April 27th, 2012

• Guide to Dividend Investing - a review

• AstraZeneca wounded but definately not out!

Dear subscriber

Perhaps you are sitting in front of your computer wondering how to cope with the ongoing economic uncertainty and financial strain.

Take a moment and think of all the things you would do if you had several hundreds or even thousands of extra pounds per month - and were worry free concerning your retirement. I am sure you came up with plenty of options how that money could be used.

Maybe you already have your money invested somewhere. But ask yourself this question - is your money working hard enough for you and are you seeing the return that you want and absolutely need to have on that investment?

Today the case for investing in inflation beating dividend paying shares is as strong, if not stronger, than ever.

When ISA’s were launched in 1999 the Bank of England base rate was 5.5% while inflation was 1.6% and falling

Today, base rate stands at 0.5%, and inflation at 3.4%, still well above the Bank’s 2% target.

Anyone holding cash is likely to be subject to a negative return after accounting for inflation. Fortunately, some of the UK’s best companies are offering dividend yields of up to 7.5%.

Instead, investing in high quality companies paying increasing dividends is a relatively safe, effective, and proven investment strategy that will grow your hard earned money, if done in the right way…

Clever investing in historically undervalued companies, with long track records of increasing dividends, at the right time can be one way to help resolve your financial investment dilemmas.

Our focus

At Dividend Income Investor.com we focus on real total return defined as dividend yield plus dividend growth plus capital gains. We look to combine:

1. “high yield” (those shares with dividend yields at least 40% higher than the FTSE100 average) with

2. “dividend growth” (companies with good dividend track records and growth potential) that are

3. “historically undervalued” (using a share’s dividend yield as the primary measure of value, investors will learn to buy and sell when dividend yields instruct them to do so) thereby maximising total real return.

The reasoning behind real total return appeals to us as long-term investors as it deals with averages – an average dividend yield, average dividend growth and average annual share price appreciation.

Of course . . .

We cannot be sure that dividends will rise in each and every year. We also cannot be sure when and to what extent share prices will rise.

However if we can buy a high quality dividend paying share at historically undervalued price levels, and, if this company has a long, uninterrupted history of dividend payments and of frequent dividend increases over a period of years, we can be pretty sure that the total return on that investment is likely to outperform the total return on any other kind of investment.

Our focus on total real return from high quality dividend paying shares could therefore help you to stay ahead of inflation, but also increase your real wealth over time.

Endorsement

“…if you can get what the author of the Guide to Dividend Investing has to say, then you are qualified beyond the 99.9% of private investors who allow their riches to be run by someone else for a huge fee…” Shares: Reaping the Dividends – Michael Wilson

The complete Guide to Dividend Investing is the comprehensive 91 page tool that you need to have in order to maximise your real total return. The Guide will help you:

• How to manage your own dividend investments so you don’t have to pay an expert, because you will now be an expert
• How to tap into the incredible market of viable low risk investment returns that many people don’t realise the potential of

  NOTE: More than 90% of the total returns in the UK stock market can be directly attributed to dividends and dividend growth

• That timing and selection is everything; you will learn when to make critical investment decisions using valuable dividend-yield patterns
• Why dividend investing can be extremely lucrative and what traps you need to be aware of

You don’t need to wonder any more about what your next financial move will be. With the Guide to Dividend Investing, you will know exactly what to do and you will see the results of your investment strategy, without having to worry or spend thousands of pounds using a financial advisor.

Order the Guide to Dividend Investing NOW so you can take the guesswork out of your investment decisions.

As a previous purchaser has said:

“I have already produced my own watch list of high dividend payers but without the thorough analysis you do. Your dividend reports are excellent. At least I don’t have to spend hours researching these companies now myself. It’s done for me”

AstraZeneca wounded but not out!

There is no way around it; AstraZeneca announced dreadful first quarter results.

First quarter revenues came in well below market expectations,falling 11 per cent to $7.35bn, short of consensus forecasts of $7.95 billion - the average of 21 estimates compiled by Bloomberg.

Pre-tax profits fell a massive 38 per cent to $2.05bn, with earnings per share also down 38 per cent from $2.08 to $1.28.

The company highlighted challenging market conditions together with the anticipated impact from the loss of exclusivity on several brands behind the fall, which is exactly what many analysts have been fearing for a while as the benefits of some patents have come to an end, whereas there is currently nothing much to counter this.

Nevertheless, AstraZeneca remains strongly cash-generative thanks to its multi-year cuts strategy. It also has promised to return value to shareholders through a progressive dividend policy and share buyback programme.

Also, AstraZeneca has not cancelled its intention to increase the dividend while maintaining cover at two times (50% of underlying earnings).

Its dividends have been well covered by earnings in recent years, so, while the company is one of few FTSE100 listed companies with substantial net cash, and, with earnings per share stagnating this year, at best, there is a good chance the dividend for 2012 will not be cut.

Click Here to finish reading this article.

Are AstraZeneca shares undervalued?

Buying dividend paying shares when they are priced too high will often lead to long-term disappointing returns.

Worse, selling in a ‘panic’ when the overall stock market is in a down trend will further disappoint your overall returns.

Make sure to benefit when a select group of high quality dividend paying companies is historically undervalued.

Let me show you whether Astrazeneca shares are historically undervalued or not. Use this information to make better informed long term buy and sell decisions.

Join the Dividend Income Investor.com community.

Use our unique share valuation service to get the share prices at which many dividend paying companies are historically undervalued and overvalued.

Enter and exit the stock market at the right time while receiving increasing dividends from companies that have been paying dividends for decades and are financially strong.

Once you are a subscriber you will never pay more for your subscription.

Till next time

Steven Dotsch
Managing editor
EMAR Publishers
Dividend Income Investor.com
Twitter.com @Investoretire

Pass it on

Know someone who'd like to receive Dividend Alerts themselves? Simply forward this link to anyone you think could benefit from our publication: https://www.early-retirement-investor.com/shares-and-dividend.html

Reclaim dividend withholding tax

ISA and SIPP investors with foreign stocks and shares are exempt from UK tax but not from foreign dividend withholding tax. Reclaiming dividend tax abroad is very much a specialist activity and is also rather laborious.

Let Taxback assist you in reclaiming what is rightfully yours.

Dividend Alerts is an unregulated product published by EMAR Publishing, publishers of Early Retirement Investor.com

EMAR Publishing is not registered as an investment advisor or financial advisor.We do not and will not provide personalised investment or financial advice, or individually advocate the purchase or sale of any security or investment. We publish opinionated information about the stock market and companies that we believe our subscribers may be interested in.

There is no guarantee that dividends will be paid. Figures are calculated using the closing prices. All gains are gross, and returns will be affected by dividend payments, dealing costs and taxes. Profits from share dealing are a form of income and subject to taxation. Tax treatment depends on individual circumstances and may be subject to change in the future. Editors or contributors may have an interest in shares featured.

Past performance and forecasts are not reliable indicators of future performance. Shares are by their nature speculative and can be volatile. Your capital is at risk so you should never invest more than you can safely afford to lose.

Information in Dividend Alerts is for general information only and is not intended to be relied upon by individual readers in making (or not making) specific investment or financial decisions. Appropriate independent advice should be obtained before making any such decision.

No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein.

© 2010 EMAR Publishing. All Rights Reserved. The content of this email may not be reproduced without the written consent of EMAR Publishing

Click for Legal Information, Disclaimer and Privacy Statement Here.